Effectiveness of first-line abiraterone versus enzalutamide among  patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study

Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population.

Source: European Journal of Cancer - June 12, 2021 Category: Cancer & Oncology Authors: Maryam Soleimani, Kevin Zou, Katherine Sunderland, Werner Struss, Bernie J. Eigl, Lucia Nappi, Christian K. Kollmannsberger, Daygen Finch, Krista Noonan, Joanna Vergidis, Muhammad Zulfiqar, Kim N. Chi, Daniel J. Khalaf Tags: Original Research Source Type: research